Digipath
CHM Cannabis
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board: 
Last Post: 12/12/2018 1:16:48 PM - Followers: 1412 - Board type: Free - Posts Today: 7

Biotech Values is a forum for discussing 
all facets of biotech investing with an emphasis
on fundamental analysis and avoiding scams.
We generally do not discuss microcap stocks.

Compilations
FDA Calendar
Biotech Buyouts/Premiums

Biotech Acronyms
'Way Back' Archive

Digipath
CHM Cannabis
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#222751  Sticky Note SGYP files bankruptcy, Bausch Health takes remaining assets. Synergy biotech_researcher 12/12/18 07:30:02 AM
#222750  Sticky Note ACIU > AC Immune and Lilly Announce License biocqr 12/12/18 07:27:29 AM
#222730  Sticky Note Corteva—the ag-biotech company to be spun from DWDP DewDiligence 12/10/18 07:57:05 PM
#222644  Sticky Note Re: Rationale for owning RVNC (addendum to #msg-144655043) DewDiligence 12/04/18 07:08:05 PM
#222600  Sticky Note Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In hptaxis 12/04/18 08:15:07 AM
#220844  Sticky Note Allergan pursuit of longer-acting toxin not a risk jbog 09/14/18 11:13:21 AM
#222756   [OT]How drug companies make you buy more medicine Titan V 12/12/18 01:16:48 PM
#222755   i believe seth klarman is a major holder linhdtu 12/12/18 11:08:44 AM
#222754   NBIX -21%/PM on phase-2b failure in pediatric Tourette syndrome: DewDiligence 12/12/18 09:20:20 AM
#222753   Recent Biotech Bankruptcies/Liquidations/Dissolutions DewDiligence 12/12/18 08:42:03 AM
#222752   FDA Rolls Out Expectations for Biosimilars, Soon-to-Be Biologics biotech_researcher 12/12/18 08:27:03 AM
#222751   SGYP files bankruptcy, Bausch Health takes remaining assets. Synergy biotech_researcher 12/12/18 07:30:02 AM
#222750   ACIU > AC Immune and Lilly Announce License biocqr 12/12/18 07:27:29 AM
#222749   CORT:earlier this year, Cushing's Syndrome and drug to north40000 12/11/18 08:44:18 PM
#222748   CORT +32% on issuance of US patent, which DewDiligence 12/11/18 06:59:51 PM
#222747   Nice try also: All quoted material was contained north40000 12/11/18 06:46:17 PM
#222746   Nice try, but the text you highlighted in DewDiligence 12/11/18 05:15:00 PM
#222745   It does pay to read to the end north40000 12/11/18 05:09:21 PM
#222744   You changed the subject, LOL. The ONCS PR DewDiligence 12/11/18 05:05:12 PM
#222743   Now in phase 1 and 2 clinical trials, north40000 12/11/18 04:56:32 PM
#222742   (ONCS)—Pharmacodynamic data don’t tell us whether there will DewDiligence 12/11/18 04:49:24 PM
#222741   MRK/ONCS: Comments? This news looks significant to me north40000 12/11/18 04:37:16 PM
#222740   mr. o... jessellivermore 12/11/18 04:17:45 PM
#222739   hahaha wrt to revance i consider retailers to linhdtu 12/11/18 01:10:39 PM
#222738   RVNC trading up to Sakura safety results was Bickema 12/11/18 01:01:02 PM
#222737   It’s mainly YE tax loss sales as many kris_kade 12/11/18 12:59:19 PM
#222736   Looks like everyone forgot about Revance. jbog 12/11/18 12:24:17 PM
#222735   AFMD - R&D day slide deck semi_infinite 12/11/18 12:18:10 PM
#222734   https://tinyurl.com/y9mllgek sab63090 12/11/18 10:41:39 AM
#222733   PTLA -7%—CHMP extends review of Ondexxa (proposed EU DewDiligence 12/11/18 09:39:30 AM
#222732   JL, what does Vascepa cost you per month? mr_o 12/10/18 08:45:48 PM
#222731   Thanks. I didn't think GRTS had much, if DewDiligence 12/10/18 07:58:28 PM
#222730   Corteva—the ag-biotech company to be spun from DWDP DewDiligence 12/10/18 07:57:05 PM
#222729   GRTS. ..Dew ..think this is more related to Whalatane 12/10/18 04:10:57 PM
#222728   GNBT—Oops: https://www.businesswire.com/news/home/20181210005781/en On DewDiligence 12/10/18 03:43:50 PM
#222727   GRTS -14% on seemingly ho-hum PR: DewDiligence 12/10/18 12:00:07 PM
#222726   MGNX -27% on partial clinical hold announced Friday DewDiligence 12/10/18 11:55:37 AM
#222725   Thanks JL. Great info. randychub 12/10/18 09:40:45 AM
#222724   Who would you acquire if you were Mr. O'Day? Bickema 12/10/18 09:35:13 AM
#222723   AXON -22%/PM on phase-2 failure: DewDiligence 12/10/18 08:32:43 AM
#222722   Big pressure on the generics: biotech_researcher 12/10/18 07:33:56 AM
#222720   GILD’s incoming CEO<—Roche executive, Daniel O’Day (according to WSJ): DewDiligence 12/09/18 08:47:18 PM
#222719   THOR too busy to put their data on dangerM 12/09/18 08:19:49 PM
#222718   I predict that, when all is said and DewDiligence 12/09/18 08:15:28 PM
#222717   Agree. <eom> kris_kade 12/09/18 07:49:39 PM
#222716   Aside from the date comments are due I'm dewophile 12/09/18 04:14:52 PM
#222715   Another tweet suggests that proposed rule available below, mouton29 12/09/18 04:13:24 PM
#222714   Probably you are correct, but there are some mouton29 12/09/18 01:03:00 PM
#222713   This is old news dewophile 12/09/18 10:40:25 AM
#222712   “DMA.V/DMAC sells 4.1M shares @$4.00 in US IPO” This FreeNorth 12/08/18 06:41:59 PM
#222711   Trump admin seeks to severely limit all biotech biotech_researcher 12/08/18 02:50:38 PM
#222710   Not for US or ROW bio companies. Actually kris_kade 12/08/18 02:38:09 PM
#222709   Bad news for biotech if true: Kenneth Harris (@kharrisCellMed) 12/7/18, biotech_researcher 12/08/18 11:05:58 AM
#222708   https://www.yahoo.com/gma/2nd-deadliest-ebola-outbreak-history-spreads-major-cit Preciouslife1 12/08/18 07:19:18 AM
#222707   randy... Sjorgren's Syndrome (SS)..is generally though of to be jessellivermore 12/08/18 06:47:33 AM
#222706   Matthew Herper (@matthewherper) 12/7/18, 11:01 AM Some personal news. After biotech_researcher 12/07/18 08:21:55 PM
PostSubject